Protein C Deficiency Overview
Learn About Protein C Deficiency
Protein C deficiency is a disorder that increases the risk of developing abnormal blood clots; the condition can be mild or severe.
Protein C deficiency is caused by mutations in the PROC gene. This gene provides instructions for making protein C, which is found in the bloodstream and is important for controlling blood clotting. Protein C blocks the activity of (inactivates) certain proteins that promote blood clotting.
Mild protein C deficiency affects approximately 1 in 500 individuals. Severe protein C deficiency is rare and occurs in an estimated 1 in 4 million newborns.
Protein C deficiency is inherited in an autosomal dominant pattern, which means one altered copy of the PROC gene in each cell is sufficient to cause mild protein C deficiency. Individuals who inherit two altered copies of this gene in each cell have severe protein C deficiency.
Pilar Medina practices in Valencia, Spain. Medina and is rated as an Elite expert by MediFind in the treatment of Protein C Deficiency. Their top areas of expertise are Protein C Deficiency, Venous Thromboembolism (VTE), Blood Clots, and Pulmonary Embolism.
Shouichi Ohga practices in Fukuoka, Japan. Ohga and is rated as an Elite expert by MediFind in the treatment of Protein C Deficiency. Their top areas of expertise are Protein C Deficiency, Aase Syndrome, Pure Red Cell Aplasia, Vitrectomy, and Bone Marrow Transplant.
Ewa Wypasek practices in Krakow, Poland. Ms. Wypasek and is rated as an Elite expert by MediFind in the treatment of Protein C Deficiency. Her top areas of expertise are Protein S Deficiency, Protein C Deficiency, Congenital Antithrombin 3 Deficiency, Coronary Artery Bypass Graft (CABG), and Heart Bypass Surgery.
Summary: This study is conducted in Japan of Freeze-dried Human Protein C Concentrate (TAK-662) used to treat participants with congenital protein C deficiency. The main aim of the study is to evaluate for adverse events and effectiveness of congenital protein C deficiency (TAK-662). During the study, participants with congenital protein C deficiency will be administered with TAK-662 intravenous injection ...
Published Date: May 01, 2013
Published By: National Institutes of Health